Silvana Luciani1, Laia Bruni2, Irene Agurto1, Cuauhtémoc Ruiz-Matus3. 1. Unit of Noncommunicable Diseases, Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization. Washington, DC, USA. 2. Cancer Epidemiology Research Program, Catalan Institute of Oncology. Barcelona, Spain. 3. Unit of Comprehensive Family Immunization, Department of Family, Gender and Lifecourse, Pan American Health Organization. Washington, DC, USA.
Abstract
OBJECTIVE: To describe HPV vaccine program implementation, monitoring and evaluation experiences in Latin America. MATERIALS AND METHODS: We reviewed published articles in peer-reviewed journals and reports from government web- sites, as well as the PAHO/WHO/UNICEF Joint Reporting form and the ICO/IARC HPV Information Centre database. RESULTS: By December 2016, 13 countries/territories in Latin America (56%) have introduced HPV vaccines. The majority have done so in the past three years, targeting 10- 12 year old girls with a two dose schedule, through school programs. Vaccine coverage ranges from 30 to 87%. Safety monitoring is well established, but monitoring vaccine impact is not, and data are not available. CONCLUSIONS: . Although Latin America is the most advanced developing region with HPV vaccine introduction, systems for its monitoring are weak and there is a paucity of consistently available coverage data for this vaccine. Challenges remain to introduce HPV vaccines in several countries, to achieve high coverage, and to strengthen monitoring, evaluation and reporting.
OBJECTIVE: To describe HPV vaccine program implementation, monitoring and evaluation experiences in Latin America. MATERIALS AND METHODS: We reviewed published articles in peer-reviewed journals and reports from government web- sites, as well as the PAHO/WHO/UNICEF Joint Reporting form and the ICO/IARC HPV Information Centre database. RESULTS: By December 2016, 13 countries/territories in Latin America (56%) have introduced HPV vaccines. The majority have done so in the past three years, targeting 10- 12 year old girls with a two dose schedule, through school programs. Vaccine coverage ranges from 30 to 87%. Safety monitoring is well established, but monitoring vaccine impact is not, and data are not available. CONCLUSIONS: . Although Latin America is the most advanced developing region with HPV vaccine introduction, systems for its monitoring are weak and there is a paucity of consistently available coverage data for this vaccine. Challenges remain to introduce HPV vaccines in several countries, to achieve high coverage, and to strengthen monitoring, evaluation and reporting.
Authors: J Smith Torres-Roman; Luz Ronceros-Cardenas; Bryan Valcarcel; Janina Bazalar-Palacios; Jorge Ybaseta-Medina; Greta Carioli; Carlo La Vecchia; Christian S Alvarez Journal: BMC Public Health Date: 2022-01-16 Impact factor: 3.295
Authors: Marco Bandini; Mohamed Ahmed; Giuseppe Basile; Nicholas Watkin; Viraj Master; Yao Zhu; Gagan Prakash; Alejandro Rodriguez; Mbaaga K Ssebakumba; Riccardo Leni; Giuseppe Ottone Cirulli; Ben Ayres; Rachel Compitello; Filippo Pederzoli; Pankaj M Joshi; Sanjay B Kulkarni; Francesco Montorsi; Guru Sonpavde; Andrea Necchi; Philippe E Spiess Journal: Nat Rev Urol Date: 2021-12-22 Impact factor: 16.430
Authors: Mona Sadat Larijani; Mir Davood Omrani; Rahim Soleimani; Anahita Bavand; Amir Houshang Nejadeh; Vahid Ezzatizadeh; Mahboubeh Jamshidi; Amitis Ramezani Journal: Biomed Res Int Date: 2022-03-18 Impact factor: 3.411